Interleukin-17 inhibition: a route to psoriasis clearance? (Q85372805)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26072106%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

title

Interleukin-17 inhibition: a route to psoriasis clearance? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26072106%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26072106%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

language of work or name

English

0 references

publication date

10 June 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26072106%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26072106%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

volume

386

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26072106%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

issue

9993

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26072106%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

page(s)

510-512

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26072106%20AND%20SRC:MED&resulttype=core&format=json

Recent advances in the IL-17 cytokine family

17 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960857-1

7 January 2021

Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960857-1

7 January 2021

Secukinumab in plaque psoriasis--results of two phase 3 trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960857-1

7 January 2021

PASI90 response: the new standard in therapeutic efficacy for psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960857-1

7 January 2021

Immunity to infection in IL-17-deficient mice and humans

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960857-1

7 January 2021

A protective function for interleukin 17A in T cell-mediated intestinal inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960857-1

7 January 2021

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960857-1

7 January 2021

Circulating levels of interleukin-17 and cardiovascular outcomes in patients with acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960857-1

7 January 2021

10.1016/S0140-6736(15)60857-1

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26072106%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

1 reference